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Background: Nuclear receptors are a class of 48 ligand-activated transcription factors identiﬁed as key players of
metabolic and developmental processes. Most of these receptors are potential targets for pharmacological strat-
egies in the Metabolic Syndrome. In the present study, we analyzed changes in the mRNA expression of nuclear
receptors in the peripheral blood mononuclear cells of patients with Metabolic Syndrome, in order to identify
novel biomarkers of disease and candidate targets for putative therapeutical approaches. Methods and results:
We enrolled thirty healthy controls (14 M:16 F) and thirty naïve patients (16 M: 14 F; N3 criteria for Metabolic
Syndrome upon Adult Treatment Panel III) without organ damage. Using quantitative real-time PCR, we assessed
the expression patterns of nuclear receptors in peripheral bloodmononuclear cells. 33/48 nuclear receptorswere
expressed in peripheral blood mononuclear cells. In patients with Metabolic Syndrome, we found a signif-
icant down-regulation of the entire PPAR, NR4A and RAR families, together with a repression of RXRα, VDR,
and Rev-Erbα. Furthermore, we performed a novel statistical analysis with classiﬁcation trees, which allowed us
to depict a predictive core of nuclear receptor expression patterns characterizing subjects with Metabolic Syn-
drome. Random Forest Analysis identiﬁedNOR1 and PPARδ, whichwere both reduced in peripheral bloodmono-
nuclear cells and speciﬁcally in CD14+ cells (mostly monocytes), as classiﬁers of Metabolic Syndrome, with high
speciﬁcity and sensitivity. Conclusions: Our results point to the use of PPAR and NR4AmRNA levels in the overall
peripheral bloodmononuclear cells as biomarkers of Metabolic Syndrome and bona ﬁde putative targets of phar-
macological therapy.© 2013 Elsevier B.V. All rights reserved.1. Introduction
Nuclear receptors (NRs) are a superfamily of ligand-dependent
and -independent transcription factors (48 in humans and 49 in
mice) [1]. NRs are intracellular sensors of different natural and/or
synthetic ligands, including hormones, leukotrienes, prostaglandins,
and nutritional compounds (e.g. dietary lipids, xenobiotics, and drugs)
[1]. When ligands are unknown, the NRs are called “orphans”. When
NRs are ligand-independent, they are called “true orphans” [1]. NRs
modulate coherent pathways involved in essential functions for the
body, including reproduction, development, cell growth and differentia-
tion, immune function, metabolic homeostasis, at a transcriptional levelch Center, IRCCS Oncologico
Tel.: +39 0805555900 (ofﬁce);
schetta).
ights reserved.[1]. Indeed, the possibility to easily pharmacologically or nutritionally
modulate the NR function highlights their value as promising pharmaco-
logical targets in different conditions, including Metabolic Syndrome
(MS), cardiovascular disease and cancer [2]. NRs are involved in the regu-
lation of a wide array of metabolic processes, ranging from fatty acid syn-
thesis and oxidation, cholesterol and bile acid metabolism, to glucose
homeostasis [2,3]. Changes in NR expression and activity are also associ-
ated with major metabolic disease, including MS [4].
MS constitutes a cluster of risk factors for an increased mortality, and
includes abdominal obesity, blood hypertension, hypertriglyceridemia,
low high-density lipoprotein cholesterol (HDL-c) and abnormal glycemia
[5,6]. Complications include diabetes mellitus type 2 and atherosclerosis,
which lead to coronary artery disease (CAD) and cerebral strokes, and in-
creased cancer risk [5,6]. The prevalence of the MS and of its complica-
tions is rapidly increasing in industrialized countries due to Western
life-style [5,6]. Thus, the study of the molecular pathways involved in
the development and progression of MS and its complications is
Table 1
Clinical characterization of the study population.
Clinical variable Control MS p-Value
n (M:F) 30 (14:16) 30 (16:14) –
Weight (kg) 66.5 ± 2.2 96.2 ± 3.8 b0.01
BMI (kg/m2) 22.5 ± 0.4 33.2 ± 0.9 b0.01
WC (cm) 85.8 ± 1.4 110.3 ± 2.3 b0.01
SBP (mm Hg) 112.3 ± 2.1 131.6 ± 2.9 b0.01
DBP (mm Hg) 69.9 ± 1.1 83.6 ± 1.7 b0.01
Glucose (mg/dl) 84.4 ± 1.1 104.0 ± 5.4 b0.01
HbA1c (%) 5.2 ± 0.1 6.1 ± 0.2 b0.01
Insulin (microUI/ml) 6.5 ± 0.4 18.3 ± 2.6 b0.01
HOMA-IR 1.4 ± 0.1 4.6 ± 0.6 b0.01
Total cholesterol (mg/dl) 184.6 ± 5.2 187.4 ± 7.1 NS
HDL-C (mg/dl) 63.3 ± 2.5 42.1 ± 2.2 b0.01
LDL-C (mg/dl) 106.6 ± 4.4 117.3 ± 6.1 NS
TG (mg/dl) 70.5 ± 5.8 156.8 ± 14.9 b0.01
AST (U/l) 26.8 ± 4.4 25.8 ± 3.0 NS
ALT (U/l) 36.0 ± 3.9 55.2 ± 6.0 b0.01
GGT (U/l) 25.3 ± 3.1 58.6 ± 22.3 0.01
ALP (U/l) 64.7 ± 4.0 86.4 ± 8.8 b0.01
BUN (mg/dl) 33.2 ± 1.3 35.3 ± 1.7 NS
Creatinine (mg/dl) 1.0 ± 0.2 0.8 ± 0.03 NS
Uric acid (mg/dl) 3.7 ± 0.2 5.2 ± 0.2 b0.01
Microalbuminuria (mg/l) 14.2 ± 1.7 23.0 ± 4.3 NS
Sodium (mEq/l) 139.0 ± 0.4 139.4 ± 0.4 NS
Potassium (mEq/l) 3.9 ± 0.04 4.1 ± 0.03 b0.01
Magnesium (mg/dl) 1.9 ± 0.04 1.9 ± 0.03 NS
Calcium (mg/dl) 8.9 ± 0.1 9.0 ± 0.1 NS
Ionized calcium (mg/dl) 3.9 ± 0.03 3.9 ± 0.03 NS
Phosphorus (mg/dl) 3.7 ± 0.1 3.6 ± 0.1 NS
ESR (mm/h) 6.3 ± 0.9 13.9 ± 1.9 b0.01
CRP (mg/dl) 0.2 ± 0 1.1 ± 0.4 b0.01
Fibrinogen (mg/dl) 205.3 ± 8.0 301.7 ± 11.7 b0.01
WBC (103/μl) 6.0 ± 0.3 7.3 ± 0.3 b0.01
Monocytes (%) 6. 2 ± 0.3 5.7 ± 0.2 NS
Lymphocytes (%) 35.0 ± 1.4 31.7 ± 1.7 NS
Neutrophils (%) 55.2 ± 1.5 58.0 ± 1.6 NS
Basophils (%) 0.5 ± 0.04 0.5 ± 0.1 NS
Eosinophils (%) 3.0 ± 0.3 3.0 ± 0.3 NS
Platelets (103/μl) 256.1 ± 11.8 277.3 ± 9.8 NS
25-OH-D (ng/ml) 32.7 ± 0.8 22.6 ± 1.5 b0.01
Cardiovascular risk (Framingham) 0.5 ± 0.2 14.3 ± 2.5 b0.01
Cardiovascular risk (Progetto Cuore) 0.2 ± 0.1 4.0 ± 1.0 NS
Data are presented asmean ± SEM. Abbreviations: 25-hydroxyvitamin D, 25-OH-D; alanine
transaminase, ALT; alkaline phosphatase, ALP; aspartate transaminase, AST; blood urea
nitrogen, BUN; Body Mass Index, BMI; C-reactive protein, CRP; diastolic blood pressure,
DBP; erythrocyte sedimentation rate, ESR; gamma-glutamyltransferase, GGT; high-density
lipoprotein cholesterol, HDL-c; homeostatic model assessment for insulin resistance,
HOMA-IR; low-density lipoprotein cholesterol, LDL-c; non-signiﬁcant, NS; systolic blood
pressure, SBP; triglyceride, TG; Waist Circumference, WC.
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cellularmodiﬁcations involving the control ofmetabolism and inﬂamma-
tion; these imbalances result in the initiation of the pathophysiological
events leading to the formation of the atheroma [7]. In this view, the in-
ﬂammatory cells play a pivotal role inmodulating all the pathophysiolog-
ical events that drive the formation of the atheroma, since they promote
the backward ﬂux of excess cholesterol from peripheral cells to the liver
for subsequent elimination, via the anti-atherogenic lipoproteins HDLs
(namely Reverse Cholesterol Transport, RCT) [8,9]. Native HDL particles
acquire cholesterol efﬂuxed from peripheral cells, through the ATP-
binding cassette (ABC) transporters A1 (ABCA1) and G1 (ABCG1)
[10–12], that are known target genes of different NRs [2,4].
Several NRs are expressed in monocytes/macrophages and modulate
the activity of the immune cells controlling cholesterol loading, and
their response to inﬂammatory stimuli within the arterial wall [13]. As a
consequence, NRs coordinate a crosstalk between the circadian rhythms,
metabolic and inﬂammatory pathways, and are able to maintain homeo-
stasis in immune cells (e.g. macrophages and lymphocytes) [13]. This is
the case of peroxisome proliferator activated receptors (PPARs), liver X
receptors (LXRs) [13], Rev-Erbs [14,15], retinoic acid receptors (RARs)
[16,17], vitamin D receptor (VDR) [18–20], and of the NR4A subfamily
that includes nerve growth factor IB (NGFIB), nuclear receptor related 1
protein (NURR1), and neuron derived orphan receptor 1 (NOR1) [21–23].
In inﬂammatory cells, PPARα inhibits the inﬂammatory responses
(reduced expression of interferon γ, INF-γ; tumor necrosis factor
α, TNF-α; tissue factor, TF; matrix metallopeptidase-9, MMP-9; and
platelet-activating factor receptor) [24], thus being beneﬁcial in
the pathophysiology of atherosclerosis. Also, PPARγ exerts an anti-
inﬂammatory activity, negatively interfering with nuclear factor κB (NF-
κB), signal transducer and activator of transcription (STAT), and activator
protein-1 (AP-1) signaling pathways, leading to a reduced expression of
pro-inﬂammatory genes encoding interleukins and other inﬂammatory
mediators (e.g. IL-2, IL-6, IL-8, TNF-α, and metalloproteases) [25]. PPARα
and PPARγ are also known to promote cholesterol efﬂux (inducing
ABCA1, ABCG1, the scavenger receptor CLA-1/SR-BI, and Niemann–Pick
type C1 and C2-NPC1 and NPC2), thus reducing intracellular lipid accu-
mulation and promoting RCT [24,26–30]. In addition, PPARγ activation
promotes the uptake of oxidized low-density lipoprotein (oxLDL), via
transcriptional induction of the scavenger receptor cluster of differentia-
tion 36 (CD36), with subsequent differentiation of the macrophages to
foam cells [13]. PPARδ is the emerging player in themodulation of inﬂam-
mation and atherosclerosis. The activation of PPARδ increases the ABCA1
expression and promotes the apolipoprotein A-I (ApoA-I)-dependent
cholesterol efﬂux [31]. Moreover, PPARδ agonists have been shown to in-
hibit the expression of TNF-α, IL-6 and vascular cell adhesion protein 1
(VCAM-1), thus leading to reduced inﬂammation [32].
Many other NRs have been proposed as modulators of the mecha-
nisms involved in the pathophysiology of atherosclerosis. This is the
case of retinoid sensors (RARs and RXRs), the NR4A subfamily, and VDR
[18,21,23,33]. In fact, RAR ligands promotemacrophage cholesterol efﬂux
by increasing ABCA1 and ABCG1 transcription [16,17,34], while the over-
expression of NR4As in humanmacrophages reduces the uptake of oxLDL
(reduced expression of scavenger receptor A -SR-A-, CD36 and CD11b),
and inhibits the production of pro-inﬂammatory cytokines and chemo-
kines (IL-1β, IL-6, IL-8, monocyte chemoattractant protein-1 and macro-
phage inﬂammatory protein-1α and -1β), thus leading to reduced foam
cell formation [21]. On the other hand, VDR, like PPARs, antagonizes the
expression of different pro-inﬂammatory genes in macrophages [18],
and the administration of vitamin D promotes the expression of the
anti-inﬂammatory transforming growth factor (TGF)-β and IL-4, and de-
creases INF-γ and TNF-α gene expression [18].
We compared the expression patterns of all members of the NR su-
perfamily in the peripheral bloodmononuclear cells (PBMCs) of healthy
subjects to those of patients withMS, in order to identify changes in the
NR transcriptome developing in an early phase of MS, and to justify
most of the pathophysiological events that lead to cardiovasculardisease. PBMCs are circulating immune cells mainly constituted by
T lymphocytes (≤70%), B lymphocytes (≤15%), natural killer cells
(≤10%), monocytes (≤5%), and dendritic cells (≤1%), which have
been recently proposed as carriers of genomic biomarkers of different
inﬂammatory diseases [35]. Indeed, PBMCs play a key role in the inﬂam-
matory system, and the changes in their gene expression are considered
predictors of the whole body inﬂammatory status in different condi-
tions [35]. Nevertheless, PBMCs contribute to the formation of early ath-
erosclerotic lesions, through the accumulation of cholesterol and the
production of inﬂammatorymediators and cytokines, and their effector
molecules are known to accelerate lesion progression [7].
In the present study,we identiﬁed different NRs in PBMCs that could
be used as candidate biomarkers and putative targets of pharmacologi-
cal therapy for the treatment of MS.2. Methods
2.1. Study population
Patient recruitment and clinical, biochemical and instrumental assess-
ment of MS were collected at the Clinica Medica “A. Murri” (“Aldo Moro”
2291S. D'Amore et al. / Biochimica et Biophysica Acta 1832 (2013) 2289–2301University Hospital of Bari, Italy). Thirty patients at the ﬁrst diagnosis of
MS (16 M:14 F; mean age 47.2 ± 2.3 yrs), and 30 healthy subjects (14
M:16 F;mean age 31.7 ± 1.2 yrs),were recruited for this study. The diag-
nosis of MS was carried out in the presence of three or more criteria for
MS according to the Third Report of the National Cholesterol Education
Program Expert Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults classiﬁcation (Adult Treatment Panel III, ATP
III) [5]. None of the subjects included in the study underwent pharmaco-
logical therapy, except for the anti-hypertensive drugs for MS patients.
Baseline characteristics of subjects are shown in Table 1. The presence
of MS complications (CAD, cerebrovascular diseases), as well as of other
diseases (e.g. endocrine disorders, hepatic or renal diseases, acute or
chronic systemic syndromes, autoimmune diseases) was the exclusion
criteria. Subjects with a daily consumption of alcohol over 25 g/day
were also excluded. In all subjects, background informationwas collected,
including lifestyle and medical history. All subjects underwent physical
examination. Body weight and height were measured using a balance
beam scale. Height and weight were used to calculate Body Mass Index
(BMI, kg/cm2). Waist Circumference (WC, cm) was assessed as a sur-
rogate marker of visceral obesity. Cardiovascular risk was assessed
using the scoring system of the Progetto Cuore [36] and of the Fra-
mingham Risk Score [37]. Blood samples were used for biochemical
measurements and for PBMC isolation, and then stored at −80 °C
until they were employed for RNA extraction and puriﬁcation. The
study protocol was approved by the Ethical Committee of the Azienda
Ospedaliero-Universitaria Policlinico di Bari, Italy. All patients gave their in-
formed consent for the use of clinical data and blood samples for scientiﬁc
research purposes connected to this project.Fig. 1. Expression levels of NRs in the PBMCs of controls and subjects with MS. Thirty-three NR
classes of expression patterns. (A) In controls, 10 NRs were highly expressed (red; Ct b
857.3 b RU b 127,312.6), 8 NRs were expressed at low levels (green; 30 b Ct b 35 or 5. 8 b R
with MS, 9 NRs were highly expressed (red; Ct b 25 or RU N 127,312.6), 18 NRs were moder
at low levels (green; 30 b Ct b 35 or 5.8 b RU b 857.8), while 16 NRs were unexpressed (blue2.2. External validation cohorts
To further validate our results, we recruited two additional external
validation cohorts of patients. In the ﬁrst cohort, we recruited 11 pa-
tients at the ﬁrst diagnosis of MS (5 M:6 F; mean age 44.8 ± 2.6 yrs),
and 11 healthy subjects (6 M:5 F; mean age 34.2 ± 2.7 yrs), with the
aimof isolating CD14+ cells (mostlymonocytes) andCD14− cells (mostly
lymphocytes) from PBMCs to conﬁrm the results we generated in the
overall PBMC population (detailed characteristics of the subjects are
shown in Supplementary Table 1). In the second cohort, we recruited
18 patients at the ﬁrst diagnosis of blood hypertension (10 M:8 F; mean
age 50.2 ± 2.2 yrs), without additional criteria for MS, who were used
to assess the accuracy of our results in theMS-negative patients with dis-
ease (detailed characteristics of the population are provided in Supple-
mentary Table 2). For the patient recruitment, we used the same criteria
listed in the previous paragraph.2.3. Biochemical measurements
After overnight fasting, serum was collected for the assessment of
standard biochemical markers of glucose and lipid metabolism, liver
and renal function, and inﬂammation by standard biochemical methods.
The determination of serum 25-hydroxyvitamin D (25-OH-D) was possi-
ble in a subgroup of 35 patients (15 controls and 20 patients with MS).
The homeostatic model assessment for insulin resistance (HOMA-IR)
was calculated by the following formula (fasting plasma glucose
(FPG) × fasting plasma insulin / 405) [38].s were expressed in the PBMCs of controls and subjects with MS. NRs were clustered in 4
25 or RU N 127,312. 6), 15 NRs were moderately expressed (yellow; 25 b Ct b 30 or
U b 857.8), while 15 NRs were unexpressed (blue; Ct N 35 or RU b 5.8). (B) In subjects
ately expressed (yellow; 25 b Ct b 30 or 857.8 b RU b 127,312.6), 6 NRs were expressed
; Ct N 35 or RU b 5.8).
Fig. 2.NRmRNA expression patterns in the PBMCs of controls and subjects withMS.When compared to healthy controls, in PBMCs of MS subjects 12 genes were down-regulated, 19 NRs
were unchanged, and 2were up-regulated. The 16 unexpressed genes are not shown. The colors of the columns reﬂect themRNA expression levels of Fig. 1. The data were normalized on
GAPDHmRNA levels, presented as relative units, and plotted as means ± SEM (* = p ≤ 0.05).
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Freshwhole blood (18 ml)was collected by standardized venipunc-
ture in EDTA anti-coagulant tubes (Vacuette®, Greiner Bio-One,
Kremsmunster, Austria). PBMCs were isolated at once, after collection of
blood samples, using a standard, previously validated protocol [39,40].
Cells were applied on 15 ml of Ficoll-Paque™ PLUS (Ge Healthcare,
Orsay, France) and centrifuged for 30 min at 460 g, 18 °C with no brake.
Mononuclear cells were obtained from the central white band of the gra-
dient, exhaustively washed in Dulbecco's phosphate-buffered saline
(Lonza, Basel, Switzerland), and were stored at−80 °C until RNA extrac-
tion, or used for the isolation of cell subpopulations (exclusively in the ex-
ternal validation cohort) by ﬂow cytometry.
2.5. Flow cytometry and cell sorting
Separated PBMCs were stained for 30 min in the dark at room tem-
perature with either phycoerythrin (PE) Mouse Anti-Human CD14
(IgG2b) antibody (BD Biosciences, Becton Dickinson, San Jose, CA; Cat.
No. 345785) or, for assessing the level of background staining of cells,
with a PE Mouse IgG2b Isotype Control antibody (BD Biosciences,
Becton Dickinson, San Jose, CA; Cat. No. 555058). Cell sorting of the
stained cells was performed with a BD FACSVantage SE ﬂow cytometer
(BD Bioscience, Becton Dickinson, San Jose, CA). In detail, the stained
cells were separated according to the density of epitope expression
and their physical characteristics; CD14+ cells (mostly monocytes)
and CD14− cells (mostly lymphocytes) were gated using a ﬂuorescence
parameter alongwith appropriate scatter parameters. Upon subsequent
re-analysis, cell purity was determined to be N98% for both subsets.
After sorting, cells were immediately lysed and used for RNA extraction
as described below.
2.6. RNA extraction and reverse-transcription
RNA was extracted from the PBMCs or cell subpopulation pellet
using QIAzol® Lysis Reagent (Qiagen, Hilden, Germany), according to
the manufacturer's instructions. To avoid possible DNA contamination,
the RNA was treated with DNAase-1 (Ambion, Foster City, CA). RNA
purity (A260/A280 N 1.75), and the concentration was checked by
spectrophotometer, while the RNA integrity was assessed by Bio-Rad
Experion™ (Bio-Rad, Hercules, CA). Only samples with Relative Quality
Index (RQI) N 8 were used for reverse-transcription. Samples were
stored in aliquot at−80 °C prior to use. All reagents, plastic ware, and
supplies used were sterile, nuclease free, and of molecular biology
grade. According to the manufacturer's instructions, cDNA was synthe-
sized by reverse-transcribing 4 μg of total RNA in a volume of 100 μl
using the High Capacity DNA Archive Kit (Applied Biosystems, Foster
City, CA). For cell subpopulations, due to the small quantity of RNA
achieved,weused aHighCapacity RNA-to-cDNAKit (Applied Biosystems,
Foster City, CA) to reverse-transcribe 10 ng of total RNA in a volume of
20 μl.
2.7. Quantitative real-time polymerase chain reaction (RTqPCR)
RTqPCR primers were designed using the Primer Express software
(Applied Biosystems, Foster City, CA), and previously validated andpub-
lished [41]. PCR assayswere performed in 96well optical reaction plates
using the ABI 7500HT system (Applied Biosystems, Foster City, CA). PCR
assayswere conducted in triplicate wells for each sample. The following
reaction mixture per well was used: 5 μl Power SYBR Green (Applied
Biosystems, Foster City, CA), 1.2 μl of primer at the ﬁnal concentration
of 150 nM, 0.8 μl RNAse free water, 3 μl cDNA (60 ng). To validate our
results in cell subpopulations, we used TaqMan® Gene Expression As-
says and TaqMan® Universal PCR Master Mix with UNG following the
manufacturer's instructions. The following PCR conditions were used:
UNG incubation at 50 °C for 2 min (only for TaqMan); then (for all theexperiments) denaturation at 95 °C for 10 min, followed by 40 cycles
at 95 °C for 15 s, then at 60 °C for 60 s. Baseline values of ampliﬁcation
plots were set automatically, and threshold values were kept constant
to obtain normalized cycle times and linear regression data. Individual
receptor PCR efﬁciencies were calculated from the slope of the resulting
standard curves, using the formula E = 10−1/slope where E is the efﬁ-
ciency [42,43]. The obtained efﬁciency was used to convert cycle times
from log to linear scale using the formula E−ct. NormalizedmRNA levels
are expressed as arbitrary (relative) units and were obtained by dividing
the averaged, efﬁciency-corrected, values for NR mRNA expression by
that of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA
expression for each sample. The resulting values were multiplied by 106
for the graphical representation of arbitrary units (to avoid values
below 1 when the expression of a gene is lower than the housekeeping
gene), and plotted as mean ± SEM. This methodology was already used
for NR proﬁling in different studies [41,44]. As previously proposed
[41,44], normalized mRNA expression levels were clustered in 4 classes
of expression patterns: absent, if the arbitrary units were below 5.8, low
if between 5.8 and 857.8, moderate if between 857.8 and 127,312.6 and
high if above 127,312.6. The arbitrary units used to deﬁne the mRNA
expression levels were obtained from the formulas above assuming a
Ct N 35 for absent, 35 b Ct b 30 for low, 30 b Ct b 25 for moderate and
Ct b 25 for high expression.
2.8. Protein extraction and Western blot analysis
PBMCs were lysed with RIPA buffer (Sigma-Aldrich, St. Louis, MO)
with a protease inhibitor cocktail (Roche, San Francisco, CA) and a phos-
phatase inhibitor cocktail (Sigma-Aldrich, St. Louis, MO). The lysates
were centrifuged at 13,000 g at 4 °C for 10 min. Protein concentrations
were determined using a method based on the Bradford assay (Bio-Rad
Protein Assay, Hercules, CA). Equal amounts of total cellular proteins
(40 μg) were separated on a 10% sodium dodecyl sulfate polyacryl-
amide gel and transferred onto nitrocellulose ﬁlters (Perkin Elmer,
Waltham, MA). Membranes were then blocked with 0.05% Tween 20 in
Tris-buffered saline/(T-TBS) + 1% bovine serum albumin (BSA), and
probed with the following primary antibodies: Mouse Anti-Human
NOR1 (R&D Systems, Minneapolis, MN; Cat. No. PP-H7833-00), Mouse
Anti-Human PPARδ (Abcam, Cambridge, UK; Cat. No. ab58137), and
Mouse Anti-Human β-Actin (Sigma-Aldrich; St. Louis, MO; Cat. No.
A5441). The membranes were washed in T-TBS and incubated with
horseradish peroxidase-conjugated secondary antibodies (Calbiochem,
San Diego, CA; Cat. No. 401515). Membranes were developed with the
enhanced chemiluminescent Western blotting reagent (GE Healthcare,
Dallas, TX). Images were acquired using a scanner Brother MFC-7320
(Brother, Bridgewater, NJ) and quantiﬁed by Image J Software. β-Actin
band intensity was used for equal loading control and for normalization.
2.9. Statistical analysis
All the data obtained were ﬁrst analyzed with classical statistical ap-
proaches to evaluate the differences among groups and the correlations
between clinical and prognostic variables and levels of expression of
speciﬁc NRs. In particular, the difference between two groups was
assessed with a Mann–Whitney U test while the differences among
multiple groups were assessed using a Kruskal Wallis test followed by
a Post-hoc analysis (Nemenyi–Damico–Wolfe–Dunn test). These initial
methods allowed us to rank the NRs according to their p-values. To ﬁnd
a correlation between continuous variables the Pearson's correlation
coefﬁcient was used. p-Values b 0.05 were considered statistically sig-
niﬁcant. The inﬂuence of potential sources of bias on the results was ex-
cluded by subgroup analysis. In particular, a 5 to 1 digit greedymatching
algorithm on propensity score was used to match patients withMS and
control subjects according to age [45]. In order to detect the NRs that
better discriminate subjects with MS from healthy controls, the ROC
curve analysis was applied only to signiﬁcant variables both separately
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Fig. 4.Correlations betweenHDL-c andNRmRNAexpression levels. In theoverall population,HDL-cwas signiﬁcantly (p b 0.05) and positively (r = 0.3) correlated toNOR1, PPARα, PPARδ,
RARγ and VDRmRNA levels. Legend: (white) control subjects; (black) MS patients; (circles) females; (triangles) males.
2295S. D'Amore et al. / Biochimica et Biophysica Acta 1832 (2013) 2289–2301and combined together. The area under the ROC curve (AUC) gave us a
measure of the capability of a NR to distinguish between the two clinical
groups.
To conﬁrm the results and to mitigate the impact of small sample
size on the study conclusions, the more recent and innovative Random
Forest Analysis [46] was applied to the same variables. A Random Forest
(RF) is a classiﬁcation algorithm consisting of an ensemble of tree-
structured classiﬁers and represents a highly accurate technique that
overcomes the problem of a low number of observations [47,48]. The
important features of RF are the identiﬁcation and classiﬁcation of rele-
vant differentially expressed genes [47], and the estimation of the error
rate related to their predictive ability. This efﬁcient approach gave us the
possibility to obtain a ranking of the genes according to the variable im-
portance measure (namely Relative Importance, RI) and to deﬁne an
“identity card” of the NRs characterizing PBMCs.
According to RF analysis, 100,000 trees were built to classify tissues.
The learning set used to grow each treewas a 632+bootstrap resample
of the observations; this means that about one-third of the cases were
left out of the sample. Treeswere allowed to grow to their full size with-
out pruning. Each nodewas split using the best among a random subset
of genes. The left-out observations (i.e. “out of bag” observations) were
then predicted to obtain the classiﬁcation error rate of the tree being
considered. Predictive ability of the algorithmwas assessed aggregating
the single tree error rates. This corresponds to an internal validation.
Therefore, the advantage is that RFmakes it unnecessary to do a second
external test, which is set to get an unbiased estimate of the error.
The estimation of RI was obtained by looking at howmuch the classi-
ﬁcation error increases (theC-Indexdecreases)when “out of bag”data for
that variable are permutated while all others are left unchanged. TheFig. 3. Correlations between markers of inﬂammation and NR mRNA expression levels. In the o
negatively (r = −0.3) correlated to PPARα andVDR, whileﬁbrinogenwithNOR1,NURR1, PPARδ
females; (triangles) males.importance metric used was the Mean Decrease in Accuracy (MDA).
The MDA is constructed by permuting the values of each variable of the
internal test set, recording the prediction and comparing it with the un-
permutated test set prediction of the variable. After obtaining a ranking
of genes based on descending order of RI, the best classiﬁers were identi-
ﬁed according to some “elbow strategy” on the graph of their measure of
importance. We set the cut-off value of RI where it abruptly collapsed (in
our dataset it happened between 0.92 — PPARδ and 0.67 — PPARα)
[47,48]. We followed Strobl et al. [49] to avoid a possible bias in the
variable selection: individual classiﬁcation trees were built using sub-
sampling without replacement and adopting a conditional permutation
scheme [50]. The advantages of RF indealingwith gene selection and clas-
siﬁcation are well documented [47,48].
All the analyseswere performed using the SAS Package (Release 9.1)
and the R Package (Version 2.12.2).
3. Results
3.1. Clinical characterization of the study population
Thirty patients with MS were compared to thirty healthy controls.
We show the baseline characteristics of the subjects in Table 1. Com-
pared to healthy controls, patients with MS presented signiﬁcantly in-
creased weight, BMI, AC, and blood pressure. From a metabolic point
of view, patients with MS were characterized by insulin resistance and
hyperglycemia, hypertriglyceridemia, decreased HDL-c, and increased
levels of the markers of inﬂammation (erythrocyte sedimentation rate,
ESR; C-reactive protein, CRP). Although within normal values, levels of
alanine transaminase (ALT), gamma-glutamyltransferase (GGT), andverall population, Erythrocyte Sedimentation Rate (ESR) was signiﬁcantly (p b 0.05) and
, RARα, Rev-Erbα, and RXRα. Legend: (white) control subjects; (black)MS patients; (circles)
Fig. 5.NRmodulation chart in controls and subjects withMS analyzed by RF analysis. (A) Schematic representation of the NR transcriptome (RTqPCR) analyzed by RF analysis (in order of
Relative Importance, RI). RF algorithm scored as best discriminators of the “MS status”NOR1 and PPARδ. The data are shown in a heatmapwith amatrix format; each single row represents
the expression of one gene in a single patient (column). To visualize the results, the expression levels of each gene are represented by a color (red: expression greater than themean; black:
expression equal to the mean; green: expression smaller than the mean). (B) Proximity matrix of the RF algorithm: on the basis of the levels of mRNA expression of NOR1 and PPARδ, RF
discriminated patients with MS from control patients in 77% of cases (C-Index = 0.77). Legend: (white) control subjects; (black) MS patients. (C and D) Representative Western blot
analysis of NOR1 and PPARδ (top panels) and β-Actin (bottom panels) protein expressions in PBMCs from healthy subjects and MS patients. (E and F) Quantiﬁcation of NOR1 and
PPARδ protein expressions, normalized to β-Actin content, revealed a signiﬁcant reduction in NOR1 and PPARδ protein levels in the PBMCs of MS patients (5 healthy controls vs. 5 MS
patients). The data are presented as mean ± SEM (* = p ≤ 0.05). (G and H) NOR1 and PPARδ mRNA expression patterns in subpopulations of CD14+ cells (mostly monocytes) and
CD14− cells (mostly lymphocytes) in an external validation cohort of 22 patients, conﬁrmed a more evident down-regulation of NOR1 and PPARδ in the CD14+ cells (mostly monocytes)
of MS patients. The data were normalized on GAPDHmRNA levels, presented as relative units, and plotted as means ± SEM (* = p ≤ 0.05).
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MS, as well as levels of uric acid, ﬁbrinogen and white blood cells
(WBC). Serum levels of 25-OH-D,measured in a subgroup of 35 patients
(15 controls and 20 patients with MS), were signiﬁcantly lower in pa-
tients with MS compared to controls. In addition both cardiovascular
risk scores (Framingham Risk Score and Progetto Cuore) resulted in-
creased, but only the Framingham score reached statistical signiﬁcance.3.2. Whole NR transcriptome in the PBMCs
With a previously validated quantitative real-time PCR (RTqPCR)
method [41,44], we assessed the NR mRNA expression pattern in the
PBMCs of both healthy controls and subjects with MS. Only 33 of the
total 48 NRswere expressed in the PBMCs, while 15members of the su-
perfamily were absent; 25 NRs were highly-moderately expressed in
control subjects, and 27 in MS patients (detailed expression patterns
are provided in Fig. 1). These results support a central role of the NRs
transcriptome in the physiology of PBMCs.3.3. Changes of NR transcriptome in the PBMCs of patients with MS
When comparing patients with MS to control subjects, we observed
signiﬁcant (p b 0.05) changes in the mRNA expression levels of 14 NRs
(details are provided Fig. 2 and Supplementary Table 3).We observed a
signiﬁcant decrease in themRNA of the “fatty acid sensors” PPAR-α and
-δ, while PPARγ reduction did not reach statistical signiﬁcance (p =
0.08). We also found decreased RAR-α and -γ, retinoid x receptor α
(RXRα) and retinoid acid receptor related orphan nuclear receptor γ
(RORγ). We observed a decrease in the mRNA expression of the NR4A
subfamily (NGFIB; NURR1 andNOR1), but NGFIB did not reach statistical
signiﬁcance (p = 0.2). Four other key players in the regulation of met-
abolic homeostasis, namely thyroid hormone receptor α (TRα), VDR,
Rev-Erbα and estrogen related receptor β (ERRβ), were signiﬁcantly
suppressed, as well as ERRα, which did not reach statistical signiﬁcance
(p = 0.09). We found only two NRs, RARβ2 and RORβ, to be up-
regulated, while the hepatocyte nuclear factor 4 γ (HNF4γ) tended to
increase (p = 0.08). These ﬁndings support a strong down-regulation
of the NRs involved in RCT promotion, and inﬂammatory response sup-
pression [2,4,33,51]. In linewith these results, both in the PBMCs and in
the cell subpopulations of subjects with MS, we found a signiﬁcant in-
crease of mRNA expression levels of the interleukin IL-1β, a potent
pro-inﬂammatory cytokine, and a major reduction of the membrane
cholesterol transporter ABCG1, known to be involved in lipid metabo-
lism and in the promotion of RCT (Supplementary Fig. 1).3.4. NRs and clinical correlations
Chronic systemic inﬂammation, PBMC activation and adhesion to
the vascular wall, as well as PBMC ability to accumulate cholesterol
and to produce inﬂammatory mediators and cytokines, are considered
early events in MS that can lead to the development of atheroma [7].
NRs can modulate inﬂammation [52–55], and as a conﬁrmation, we
found intriguing correlations of ESR with PPARα, and VDR, and of ﬁbrin-
ogen with PPARδ, NOR1, NURR1, RARα, Rev-Erbα, and RXRα (Fig. 3). NR
activation in PBMCs is also associated to themodulation of lipid metab-
olism, and in particular to the HDL formation and the promotion of the
RCT pathway [55–57]; we thus tested if serumHDLwas correlated with
NRs mRNA expression levels. Interestingly PPARα, PPARδ, NOR1, RARγ
and VDRmRNA levels were signiﬁcantly and positively correlated with
HDL-c (Fig. 4). All the correlations found in the overall population
were not conﬁrmed in the subgroups, except for PPARα and VDR,
which were signiﬁcantly and positively correlated (r = 0.4; p = 0.05)
with HDL-c in the control group but not in the MS group (data not
shown).3.5. NRs as candidate biomarkers of MS
We analyzed our datawith the novel Random Forest Analysis to high-
light the best discriminators (in order of relative importance, RI) of the
MS. We found NOR1 and PPARδ to be the best discriminators of the “MS
status” (Fig. 5A). The reduction of theseNRswas also conﬁrmed at protein
level in the PBMCs ofMSpatients (Fig. 5C andD). In an external validation
cohort composed of control subjects (n = 11) andMS patients (n = 11;
see the description of the population study in Supplementary Table 1),we
tested if the differences in these top hits were conﬁrmed in the ﬂow-
sorted subpopulations of CD14+ cells (mostly monocytes) and CD14−
cells (mostly lymphocytes). We conﬁrmed the down-regulation of
NOR1 in MS patients in both cell subpopulations (the statistical signiﬁ-
cance was achieved exclusively in the CD14+ compartment), while
PPARδ tended to be reduced exclusively in the CD14+ cells, but did not
reach statistical signiﬁcance (Fig. 5G–H).
We then checked the ability of the transcripts of these twoNRs in the
whole PBMC population to act as candidate biomarkers of the “MS sta-
tus”, using another feature of the RF analysis (C-Index). The RF algo-
rithm allowed us to study of the discrimination ability of a speciﬁc set
of genes, and to test the power of this prediction for new samples (1/3
of the study population acting as internal controls). On the basis of the
expression levels of NOR1 and PPARδ, RF was able to discriminate “con-
trol” from “MS status” in 77% of cases (C-Index = 0.77, see proximity
matrix, Fig. 5B). We conﬁrmed the ability of NOR1 and PPARδ as bio-
markers, calculating the ROC curves. The ROC curve of NOR1 was char-
acterized by high speciﬁcity but low sensitivity; conversely the ROC
curve of PPARδwas characterized by high sensitivity but low speciﬁcity
(Fig. 6A). In order to further test the accuracy ofNOR1 and PPARδ cut-off
values in classifying the “MS status”we validated our results in a second
validation cohort of patients with blood hypertension without other
criteria forMS (see the description of the population study in Supplemen-
tary Table 2). Intriguingly, themRNA levels ofNOR1 and PPARδ in patients
with blood hypertension (but noMS) were really similar to controls and,
using the cut-off values suggested by the ROC curves, were classiﬁed as
“NOMS” (Fig. 6B). Matching together these two NRs [possible formulae:
PPARδ + NOR1; 1 / PPARδ ∗ 1 / NOR1; 1 / (PPARδ + NOR1)], we were
able to document really high speciﬁcity and sensitivity of these combined
indicators in predicting the “MSstatus” (Fig. 6C),with an accuracy of 100%
in classifying patients with blood hypertension as “NOMS” (Fig. 6D).
4. Discussion
MS is a complex condition, characterized by a cluster of risk factors
for CAD, including central obesity, hypertension, hyperinsulinemia and
insulin resistance, atherogenic dyslipidemia, inﬂammation and a pro-
thrombotic state [5,58]. The inﬂammatory systemhas been strongly im-
plicated in the pathophysiology of MS, since the adipose tissue enlarge-
ment characterizing this condition is associated to the production of
adipose tissue-derived pro-inﬂammatory signals, leading to macrophage
recruitment and accumulation, “adiposopathy”, insulin resistance, and
atherosclerosis [2,7,59]. On the other hand, macrophages are principal
agents in the formation of the anti-atherogenic lipoproteins HDL, which
act as scavengers of excess cholesterol from peripheral tissues, including
atheroma, enhancing the RCT [8,9]. The inﬂammatory cells, and in partic-
ular PBMCs, are thus crucial in both inﬂammatory responses and meta-
bolic homeostasis, being also active players in the pathophysiology of
atherosclerosis [60]. Furthermore, the levels of mRNA expression of
speciﬁc genes in PBMCs have been recently proposed as candidate bio-
markers for an early diagnosis of different conditions, including inﬂam-
matory diseases [35].
In the presentwork, we studied the changes of theNR transcriptome
in the PBMCs of MS subjects, in order to address NR involvement in the
pathophysiological changes (metabolism and inﬂammation), which are
pathognomonic of MS and atherosclerosis [54]. NRs are transcription fac-
tors, acting asmaster transcriptional regulators ofmetabolic homeostasis,
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date players in the metabolic scenario that drives MS to atherosclerosis
[1]. Several members of the NR superfamily play an important role in
the maintenance of the metabolic homeostasis in response to distinct
stimuli (hormonal, nutrient, inﬂammatory and metabolic signals). In
PBMCs of control subjects, we found that twenty-ﬁve NRs were highly-
moderately expressed, while twenty-seven were in MS patients. In MS
patients, we observed a down-regulation of the “fatty acid sensors”
PPARα, PPARδ and PPARγ, acting as heterodimers of RXRα that was also
repressed. All PPARs are known to exert anti-inﬂammatory activity (in
macrophages and endothelial cells), by inhibiting the expression of pro-
inﬂammatory genes (pro-inﬂammatory eicosanoids and cytokines, me-
talloproteinases, and downstream targets of the NF-κB and of the AP-1)
[61,62]. PPARδ ablation in macrophages renders these cells incapable of
the transition to the anti-inﬂammatoryM2 phenotype, thus leading to in-
creased inﬂammation, peripheral “adiposopathy”, and insulin resistance
[63]. Additionally, PPARα and PPARδ activation is coupled by increased
HDL-c [64,65]; in fact, in macrophages and other cells, PPARs stimulate
the ABCA1- and ABCG1-mediated cholesterol efﬂux [2,30,64,65]. Also,
+294 t/c polymorphism in the PPARδ gene is associatedwith ametabolic
trait and higher plasma HDL-c levels [66]. We found that PPARα and
PPARδ were negatively correlated with markers of inﬂammation (ESR
and ﬁbrinogen) and positively correlated with HDL-c further conﬁrming
PPARs as central actors in the modulation of inﬂammatory processes, in
the promotion of RCT and in the protection fromCAD. Even if the changes
in the mRNA expression of the cholesterol transporters in circulating
monocytes/macrophages have a minimal contribution to plasma HDL-c
levels [67], recent observations have shown that pro-inﬂammatory M1
macrophages in peripheral tissues in obesity could derive fromcirculating
cells, rather than from a conversion ofM2macrophages [59]. In this view,
themodulation in PPARs thatwe observed could reﬂect a systemic down-
regulation of these transcriptional signals in peripheral tissues leading to
reduced RCT and enhanced inﬂammation. As conﬁrmation, we found a
signiﬁcant increase in the mRNA levels of the interleukin IL-1β, and a
signiﬁcant decrease in themRNAexpressionofABCG1 in the PBMCs of pa-
tients with MS.
Vitamin A and its derivatives, the retinoids, exertmanybiological ac-
tivities, ranging from cell proliferation, differentiation, and apoptosis to
the homeostatic control of the endocrine system [16]. Two classes of en-
docrine NRs mediate these effects: RXRs and RARs. There are studies
highlighting that RAR and RXR activation could be beneﬁcial for the
modulation of metabolic homeostasis, since RAR ligands increase
apoA-I/HDL mediated cholesterol efﬂux from macrophages by increas-
ing ABCA1 and ABCG1 transcription [16,17,34], and RXR agonists pro-
mote insulin sensitivity [68].
Intriguingly, RXRα, RARα, and RARγ were down-regulated in our
dataset, and signiﬁcantly and positively correlated with HDL-c. The
changes we observed in these NRs could be crucial in justifying the al-
terations in PBMC physiology that could lead to reduced RCT and ath-
erosclerosis. On the other hand, we found that RARβ, known to be
almost absent in inﬂammatory cells [69], was increased in patients
with MS. The role of RARβ in the regulation of metabolism and inﬂam-
mation is still elusive. If RARβ appears to have no effects in RCT promo-
tion [16], this NR has been shown to be involved in the regulation of cell
proliferation and survival [68]. Themeaning of this adaptive response in
the PBMCs of patients with MS needs to be further addressed.
The NR4A subfamily (NGFIB, NURR1 and NOR1) was also down-
regulated in MS patients. The NR4As are true orphan NRs that do not
require ligand-binding to be activated; as a consequence protein ex-
pression is closely correlated with their activity. The fact that NOR1Fig. 6.NOR1 andPPARδ transcripts in PBMCs as candidate biomarkers ofMS. (A) The ROC curve
of PPARδwas characterized by high sensitivity but low speciﬁcity. (B) The cut-off values obtain
blood hypertension, characterized by mRNA levels of these NRs very similar to controls, as wit
curve ofNOR1 and PPARδmatched together [PPARδ + NOR1; 1 / PPARδ ∗ 1 / NOR1; 1 / (PPARδ
with 100% accuracy in predicting patients with blood hypertension as “NOMS”. The data of pat
relative units; each patient is represented by a dot.was negatively correlated to the ﬁbrinogen and positively correlated
to HDL-c, further conﬁrms NOR1 as a central player in modulating im-
mune cell physiology [33,51]. Even if the bonemarrowNR4Aexpression
does not play dominant roles in macrophage polarization or in the de-
velopment of atherosclerosis in mice [70], previous studies have de-
scribed NR4As as targets of inﬂammatory pathways, acting as pro- or
anti-inﬂammatory players, depending on the cell type and the experi-
mental setting [21,23,33,51]. It is still unclear whether NR4As promote
inﬂammation or mediate pro-resolution responses. In fact, the deﬁcien-
cy of NOR1 is associated to decreased monocyte adhesion and athero-
sclerosis [51] but, on the other hand, NR4A over-expression inhibits
macrophage activation, reduces human macrophage lipid loading, and
decreases foam cell formation/differentiation [21,23]. Whether NR4A
could modulate the inﬂammation and the pathophysiology of athero-
sclerosis is still debated in literature [21,23,70].
We found a down-regulation in both VDRmRNA levels in the PBMCs
and 25-OH-D circulating levels, which were also signiﬁcantly and
positively correlated (r = 0. 4; p b 0.05). Vitamin D is known to
be immuno-modulatory, anti-inﬂammatory, anti-atherosclerotic, and
cardio-protective [20,71]. VDR activation in macrophages inhibits ath-
erosclerosis formation in mice [20], while VDR null mice develop cardio-
vascular disease [20,71]. A negative correlation between levels of vitamin
D, and cardiovascular risk/mortality also exists in humans [71]. Our
data support an early and signiﬁcant down-regulation of the vitamin
D-governed pathway that could be a predictor of worse prognosis, and
a possible target of novel integrative approaches in the treatment of MS
and in the prevention of cardiovascular events.
We also found the orphan NR Rev-Erbα to be statistically down-
regulated. This NR is primarily involved in themodulation of the circadian
clock (controlling the expression of clock and Bmal-1), and also manifests
an active role in the control of metabolism. In fact, recent studies have
shown that deletion of clock and Bmal-1 genes leads not only to circadian
disturbances, but also to metabolic abnormalities of lipid and glucose ho-
meostasis, which are reminiscent of the MS phenotype [72]. In addition,
Rev-Erb agonists decrease diet-induced obesity and markedly improve
dyslipidemia and hyperglycemia inmice [14].We found negative correla-
tions of Rev-Erbα with ﬁbrinogen, a fact that further conﬁrms previous
observations in mice highlighting the anti-inﬂammatory role of Rev-
Erbα (repression of the pro-thrombotic and pro-inﬂammatory AP-I)
[73]. The Rev-Erbα-controlled pathway, integratingmetabolic and inﬂam-
matory signals with circadian rhythms, could be central not only as a link
between altered circadian rhythms and the development of MS [15], but
also for the onset of MS complications.
In order to rank the best genes in discriminating metabolic subjects
from healthy controls, we analyzed our data with the novel RF algo-
rithmwith the aim of deﬁning a novel set of biomarkers of the “MS sta-
tus”. The RF analysis identiﬁed NOR1 and PPARδ as discriminators of MS
subjects. With the RF algorithm, we then checked the ability of these
two speciﬁc genes to classify subjects with MS from controls, and we
found a prediction ability of 77% in the overall population, which was
conﬁrmed by the ROC curve of these two NRs combined together (sen-
sitivity = 80%; speciﬁcity = 80%). As conﬁrmation, in an external vali-
dation cohort of patients with blood hypertension, we were able to
show that the NOR1 and PPARδ cut-off values were not affected by dis-
turbances in accuracy for MS detection. Furthermore, we were able to
conﬁrm the reduction of NOR1 and PPARδ in the protein levels of the
PBMCs, and in the mRNA transcripts of the CD14+ cells (mostly mono-
cytes) of MS subjects.
Given the role of PBMCs in inﬂammation, RCT, and atherosclerosis,
and since PBMC isolation and gene expression analysis can be simplyofNOR1was characterized by high speciﬁcity but low sensitivity; conversely the ROC curve
ed with the ROC curves were able to classify an external validation cohort of patients with
hout MS (“NO MS”) with accuracy of 89% for NOR1 and of 100% for PPARδ. (C–D) The ROC
+ NOR1)], documented really high speciﬁcity and sensitivity in predicting the “MS status”,
ients with blood hypertension were normalized on GAPDHmRNA levels, and presented as
2300 S. D'Amore et al. / Biochimica et Biophysica Acta 1832 (2013) 2289–2301performed, this approach could be used in a clinical setting to identify
MS subjects at risk of CAD early. Overall, our data provide a comprehen-
sive ﬂowchart of NR expression levels in PBMCs of subjects with MS,
with changes in speciﬁc hits that could be used as novel classiﬁers for
cardio-metabolic risk.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2013.09.006.
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